01:01 PM EDT, 10/13/2025 (MT Newswires) -- Actinium Pharmaceuticals ( ATNM ) shares were up nearly 6% in recent Monday trading after the company said preclinical data showed that ATNM-400 radiotherapy candidate demonstrated potent anti-tumor activity in EGFR-mutated non-small cell lung cancer models.

The preclinical study also showed that ATNM-400 was capable of overcoming resistance to osimertinib, a treatment for non-small cell lung cancer, to which patients typically develop resistance within two to three years.

Actinium said the findings will be presented Oct. 22-26 at an international cancer research conference in Boston.

Price: 1.58, Change: +0.09, Percent Change: +5.70